Identification of cancer genes by mutational profiling of tumor genomes (Q28239452)

Cancer genes and the pathways they control

Europe PubMed Central

title

Identification of cancer genes by mutational profiling of tumor genomes (English)

0 references

Sabrina Arena

2

0 references

Alberto Bardelli

object named as

Alberto Bardelli

series ordinal

3

0 references

author name string

Silvia Benvenuti

series ordinal

1

0 references

language of work or name

English

0 references

publication date

21 March 2005

0 references

published in

FEBS Letters

0 references

volume

579

0 references

issue

8

0 references

page(s)

1884-90

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.02.015

The multistep nature of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.02.015

Mutational analysis of gene families in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.02.015

A census of human cancer genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.02.015

Mutations of the BRAF gene in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.02.015

The PIK3CA gene is mutated with high frequency in human breast cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.02.015

High frequency of mutations of the PIK3CA gene in human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.02.015

21 January 2018

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.02.015

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.02.015

Form and Function of Retroviral Proviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.02.015

Avian leukosis virus-induced tumors have common proviral integration sites and synthesize discrete new RNAs: oncogenesis by promoter insertion

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.02.015

Activation of a cellular onc gene by promoter insertion in ALV-induced lymphoid leukosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.02.015

Passage of phenotypes of chemically transformed cells via transfection of DNA and chromatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.02.015

Transforming activity of human tumor DNAs

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.02.015

Human EJ bladder carcinoma oncogene is homologue of Harvey sarcoma virus ras gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.02.015

Mechanism of activation of a human oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.02.015

A point mutation is responsible for the acquisition of transforming properties by the T24 human bladder carcinoma oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.02.015

Proteins encoded by genes involved in chromosomal alterations in lymphoma and leukemia: clinical value of their detection by immunocytochemistry

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.02.015

Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.02.015

Mutation and cancer: statistical study of retinoblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.02.015

Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.02.015

Mutational analysis of the tyrosine kinome in colorectal cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.02.015

The protein kinase complement of the human genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.02.015

Oncogenic kinase signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.02.015

Protein tyrosine phosphatases in the human genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.02.015

Phosphoregulators: protein kinases and protein phosphatases of mouse.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.02.015

Mutational analysis of the tyrosine phosphatome in colorectal cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.02.015

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.02.015

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.02.015

High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.02.015

Medicine. Why a new cancer drug works well, in some patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.02.015

Oncogenomics and the development of new cancer therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.02.015

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.02.015

Imatinib as a paradigm of targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.02.015

Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.02.015

Gain-of-function mutation at the extracellular domain of KIT in gastrointestinal stromal tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.02.015

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.02.015

Trastuzumab: hopes and realities

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.02.015

RAF/RAS oncogenes and mismatch-repair status

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.02.015

Fused transcript of abl and bcr genes in chronic myelogenous leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.02.015